12/19
09:59 am
incy
Incyte Co. (NASDAQ: INCY) had its price target raised by analysts at Wells Fargo & Company from $68.00 to $70.00. They now have an "equal weight" rating on the stock.
Low
Report
Incyte Co. (NASDAQ: INCY) had its price target raised by analysts at Wells Fargo & Company from $68.00 to $70.00. They now have an "equal weight" rating on the stock.
12/19
07:25 am
incy
Incyte Corporation Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- INCY
Low
Report
Incyte Corporation Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- INCY
12/18
07:30 am
incy
Levi & Korsinsky Reminds Incyte Corporation Investors of the Ongoing Investigation into Potential Violations of Securities Laws - INCY
Low
Report
Levi & Korsinsky Reminds Incyte Corporation Investors of the Ongoing Investigation into Potential Violations of Securities Laws - INCY
12/17
10:06 am
incy
Incyte Co. (NASDAQ: INCY) is now covered by analysts at UBS Group AG. They set a "neutral" rating and a $77.00 price target on the stock.
Low
Report
Incyte Co. (NASDAQ: INCY) is now covered by analysts at UBS Group AG. They set a "neutral" rating and a $77.00 price target on the stock.
12/17
08:00 am
incy
Incyte to Present at Upcoming Investor Conference
Low
Report
Incyte to Present at Upcoming Investor Conference
12/17
07:25 am
incy
Incyte Corporation (INCY) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
Low
Report
Incyte Corporation (INCY) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
12/16
07:25 am
incy
Investors who lost money on Incyte Corporation should contact Levi & Korsinsky about an ongoing investigation - INCY
Low
Report
Investors who lost money on Incyte Corporation should contact Levi & Korsinsky about an ongoing investigation - INCY
12/13
11:05 pm
incy
Incyte Co. (NASDAQ: INCY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Low
Report
Incyte Co. (NASDAQ: INCY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
12/13
12:22 pm
incy
Incyte Co. (NASDAQ: INCY) had its "outperform" rating re-affirmed by analysts at William Blair.
Low
Report
Incyte Co. (NASDAQ: INCY) had its "outperform" rating re-affirmed by analysts at William Blair.
12/13
07:30 am
incy
Incyte Corporation Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - INCY
Medium
Report
Incyte Corporation Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - INCY
12/12
07:25 am
incy
An Investigation Has Commenced on Behalf of Incyte Corporation Shareholders. Contact Levi & Korsinsky to Discuss your INCY Losses
Low
Report
An Investigation Has Commenced on Behalf of Incyte Corporation Shareholders. Contact Levi & Korsinsky to Discuss your INCY Losses
12/11
07:25 am
incy
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Incyte Corporation (INCY)
Low
Report
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Incyte Corporation (INCY)
12/10
10:43 am
incy
Adding Tafasitamab Cuts Risk of Disease Progression, Relapse, or Death in Patients with Recurrent or Refractory Follicular Lymphoma [Yahoo! Finance]
Low
Report
Adding Tafasitamab Cuts Risk of Disease Progression, Relapse, or Death in Patients with Recurrent or Refractory Follicular Lymphoma [Yahoo! Finance]
12/10
10:39 am
incy
Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma [Yahoo! Finance]
Low
Report
Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma [Yahoo! Finance]
12/10
10:30 am
incy
Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
Low
Report
Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma
12/10
10:05 am
incy
Graft Versus Host Disease (GvHD) Treatment Market Outlook, 2024-2028 & 2033 - Revenue Shares for Corticosteroids, Monoclonal Antibodies, Immunosuppressants and Other Products [Yahoo! Finance]
Low
Report
Graft Versus Host Disease (GvHD) Treatment Market Outlook, 2024-2028 & 2033 - Revenue Shares for Corticosteroids, Monoclonal Antibodies, Immunosuppressants and Other Products [Yahoo! Finance]
12/10
07:25 am
incy
INCY ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Incyte Corporation
Low
Report
INCY ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Incyte Corporation
12/9
02:52 pm
incy
Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals [Yahoo! Finance]
Low
Report
Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals [Yahoo! Finance]
12/9
07:25 am
incy
Levi & Korsinsky Reminds Incyte Corporation Investors of the Ongoing Investigation into Potential Violations of Securities Laws - INCY
Medium
Report
Levi & Korsinsky Reminds Incyte Corporation Investors of the Ongoing Investigation into Potential Violations of Securities Laws - INCY
12/7
07:31 am
incy
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer [Yahoo! Finance]
Medium
Report
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer [Yahoo! Finance]
12/7
07:30 am
incy
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
Medium
Report
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
12/6
04:30 pm
incy
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/6
07:25 am
incy
ATTENTION Incyte Corporation Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
Low
Report
ATTENTION Incyte Corporation Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
12/5
07:36 am
incy
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now? [Yahoo! Finance]
Low
Report
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now? [Yahoo! Finance]
12/5
07:30 am
incy
INCY STOCK ALERT: Levi & Korsinsky Notifies Incyte Corporation Investors of an Ongoing Investigation
Low
Report
INCY STOCK ALERT: Levi & Korsinsky Notifies Incyte Corporation Investors of an Ongoing Investigation